Pancreatic Cancer Medical Services in China

Pancreatic cancer is a highly aggressive malignancy arising from the exocrine or endocrine cells of the pancreas, with pancreatic ductal adenocarcinoma (PDAC) accounting for over 90% of cases. Due to its deep anatomical location and nonspecific early symptoms—such as weight loss, jaundice, abdominal pain, and new-onset diabetes—it is frequently diagnosed at advanced stages. Five-year overall survival remains low, particularly for locally advanced or metastatic disease, underscoring the critical importance of timely, multidisciplinary intervention. Treatment modalities include surgical resection (e.g., Whipple procedure or distal pancreatectomy), neoadjuvant/adjuvant chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), radiation therapy—including stereotactic body radiotherapy (SBRT)—and emerging options like targeted therapy and immunotherapy for select molecular subtypes.

China offers distinct advantages in pancreatic cancer management: leading oncology centers employ internationally trained specialists proficient in minimally invasive and robotic-assisted surgery; state-of-the-art imaging (3T MRI, PET-CT) and precision radiotherapy platforms enable accurate staging and dose-escalated treatment; robust clinical trial participation supports access to novel agents; and published outcomes demonstrate comparable R0 resection rates and progression-free survival to Western benchmarks—often at 40–60% lower total costs than the US or EU. As a dedicated medical tourism agency, we facilitate seamless care for international patients: vetting JCI-accredited hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, arranging visas and accommodation, and providing bilingual clinical liaison and post-treatment follow-up support—ensuring continuity, transparency, and personalized navigation through every phase of care.

Treatment Options & Itemized Cost Breakdown: Pancreatic Cancer (Oncology Department)

Non-Surgical / Medical Management

*Indicated for unresectable, metastatic, or medically inoperable disease; requires histopathological confirmation and staging (CT/MRI + CA19-9).*

• •First-line systemic therapy (FOLFIRINOX or Gemcitabine + Nab-paclitaxel):

- Supportive care (antiemetics, growth factors, hydration): $180–$320/cycle - Monitoring labs (CBC, LFTs, renal panel, CA19-9): $110–$160/cycle - Imaging (contrast-enhanced CT/MRI every 2 cycles): $480–$720/study

• •Palliative radiotherapy (SBRT or conventional EBRT):

- Fractionated course (15–25 fractions): $1,800–$3,100

• •Symptom control (biliary stenting, pain management):

- Celiac plexus neurolysis (CT-guided): $850–$1,200

Surgical / Interventional Options

*Eligibility: Resectable (no distant mets, no SMA/CHA encasement >180°, no portal vein invasion requiring reconstruction), ECOG ≤2, adequate cardiac/pulmonary reserve.*

• •Preoperative workup (mandatory):

- Cardiopulmonary evaluation (EKG, echo, PFTs if indicated): $290–$410 - Nutritional assessment + albumin/prealbumin: $65

• •Surgical procedures:

- Distal pancreatectomy ± splenectomy: $6,400–$9,300 - Total pancreatectomy: $9,100–$13,500 - Intraoperative ultrasound + frozen section: $380

• •Post-op pathology + molecular testing (KRAS/NRAS/BRAF, MSI, NTRK): $450–$890

Special/Complex Condition Management

• •Borderline resectable disease (with vascular abutment): Neoadjuvant chemoRT (FOLFIRINOX × 4 cycles + concurrent RT): $14,200–$18,500 total
• •Locally advanced unresectable: Stereotactic body radiotherapy (SBRT) + gemcitabine maintenance: $10,800–$13,600
• •BRCA1/2-mutated metastatic disease: PARP inhibitor (Olaparib) maintenance post-platinum: $2,100/month (first-line approved in China per NMPA)
• •Periampullary adenocarcinoma with duodenal involvement: Extended Whipple + intraoperative radiation (IORT): $15,400–$19,800

Quick Selection Guide

• •Fit, resectable patient (<75 y, no major comorbidities): Whipple + adjuvant gemcitabine/capecitabine — optimal survival benefit; total cost ~$11,500–$15,200.
• •Unresectable locally advanced, good PS: Neoadjuvant FOLFIRINOX → reassessment → SBRT if conversion — balances efficacy and toxicity; ~$16,000–$18,500.
• •Metastatic, elderly (>75 y) or frail: Gemcitabine monotherapy + best supportive care — lower toxicity, median cost $4,800–$7,200 over 4–6 months.
• •Budget-constrained (<$5,000): Palliative biliary stenting + symptom-directed RT + oral capecitabine — focuses on QoL; total ~$4,100–$4,900.
• •BRCA+ metastatic: Platinum-based chemo → olaparib maintenance — targeted, durable response; first-year cost ~$28,000 (includes genetic testing + drug).